Literature DB >> 9828224

Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis.

K Thompson1, J Maltby, J Fallowfield, M McAulay, H Millward-Sadler, N Sheron.   

Abstract

Kupffer cells (KC) play a central role in the initiation and perpetuation of hepatic inflammation, which, if uncontrolled, can result in tissue damage, fibrosis, and cirrhosis. Interleukin-10 (IL-10) can inhibit a range of macrophage functions. We hypothesized that the transcription, synthesis, and release of IL-10 may influence the development of liver injury. Rat KC were activated in vitro with lipopolysaccharide (LPS), and expression of IL-10 mRNA compared with IL-13 and IL-1beta by reverse-transcription polymerase chain reaction (RT-PCR). The effects of pretreatment with recombinant IL-10 (rIL-10) on KC phagocytosis, production of superoxide (SO), and tumor necrosis factor (TNF-) were examined by fluorescent activated cell sorter (FACS), reduction of ferricytochrome C, and bioassay, respectively. Rats were administered intraperitoneal carbon tetrachloride (CCl4), and expression of IL-10 mRNA and protein in vivo compared with IL-13 and IL-1beta by RT-PCR and immunoblotting. Results were correlated with histological inflammatory changes. Finally, IL-10 gene-deleted (IL-10-/-) mice and wild-type (WT) controls were administered intraperitoneal CCl4 biweekly for up to 70 days, and the development of inflammation and fibrosis compared by scoring histological changes. IL-10 mRNA was up-regulated early, both in KC in vitro and in whole liver in vivo, concurrent with that of IL-1beta. IL-10 was able to inhibit KC production of both SO and TNF- in vitro, and this was achieved more effectively than IL-4 or IL-13; no such effects were seen on KC phagocytosis. After 70 days of treatment with CCl4, IL-10-/- mice showed significantly more severe fibrosis and exhibited higher hepatic TNF- levels than WT controls. These results suggest that IL-10 synthesized during the course of liver inflammation and fibrosis may modulate KC actions, and influence subsequent progression of fibrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828224     DOI: 10.1002/hep.510280620

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  73 in total

Review 1.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 2.  Cirrhosis: new research provides a basis for rational and targeted treatments.

Authors:  John P Iredale
Journal:  BMJ       Date:  2003-07-19

Review 3.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

4.  Lymphocyte-hepatic stellate cell proximity suggests a direct interaction.

Authors:  N Muhanna; A Horani; S Doron; R Safadi
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

Review 5.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 6.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 7.  Interleukin-10 and chronic liver disease.

Authors:  Li-Juan Zhang; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

8.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

9.  IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans.

Authors:  Fawaz Alzaid; Floriane Lagadec; Miguel Albuquerque; Raphaëlle Ballaire; Lucie Orliaguet; Isabelle Hainault; Corinne Blugeon; Sophie Lemoine; Agnès Lehuen; David G Saliba; Irina A Udalova; Valérie Paradis; Fabienne Foufelle; Nicolas Venteclef
Journal:  JCI Insight       Date:  2016-12-08

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.